menu
    • menu
    [{"orgOrder":0,"company":"Meabco","sponsor":"Meddoc | Norwegian University of Life Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Cytotoxic Drug","year":"2016","type":"Inapplicable","leadProduct":"BP-C1","moa":"DNA","graph1":"Oncology","graph2":"Phase II","graph3":"Meabco","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Meabco \/ Meddoc | Norwegian University of Life Sciences","highestDevelopmentStatusID":"8","companyTruncated":"Meabco \/ Meddoc | Norwegian University of Life Sciences"},{"orgOrder":0,"company":"Meabco","sponsor":"Meddoc | Norwegian University of Life Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Cytotoxic Drug","year":"2018","type":"Inapplicable","leadProduct":"BP-C1","moa":"DNA","graph1":"Oncology","graph2":"Phase II","graph3":"Meabco","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Meabco \/ Meddoc | Norwegian University of Life Sciences","highestDevelopmentStatusID":"8","companyTruncated":"Meabco \/ Meddoc | Norwegian University of Life Sciences"},{"orgOrder":0,"company":"Meabco","sponsor":"Meddoc | Norwegian University of Life Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Cytotoxic Drug","year":"2018","type":"Inapplicable","leadProduct":"BP-C1","moa":"DNA","graph1":"Oncology","graph2":"Phase II","graph3":"Meabco","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Meabco \/ Meddoc | Norwegian University of Life Sciences","highestDevelopmentStatusID":"8","companyTruncated":"Meabco \/ Meddoc | Norwegian University of Life Sciences"},{"orgOrder":0,"company":"Meabco","sponsor":"Meddoc | Norwegian University of Life Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Cytotoxic Drug","year":"2018","type":"Inapplicable","leadProduct":"BP-C1","moa":"DNA","graph1":"Oncology","graph2":"Phase II","graph3":"Meabco","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Meabco \/ Meddoc | Norwegian University of Life Sciences","highestDevelopmentStatusID":"8","companyTruncated":"Meabco \/ Meddoc | Norwegian University of Life Sciences"},{"orgOrder":0,"company":"Meabco","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Cytotoxic Drug","year":"2013","type":"Inapplicable","leadProduct":"BP-C1","moa":"DNA","graph1":"Oncology","graph2":"Phase II","graph3":"Meabco","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Meabco \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Meabco \/ Undisclosed"},{"orgOrder":0,"company":"Meabco","sponsor":"Meddoc | Norwegian University of Life Sciences | Meddoc Research Indonesia | Meddoc Research Taiwan","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"BP-C1","moa":"DNA","graph1":"Oncology","graph2":"Phase II","graph3":"Meabco","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Meabco \/ Meddoc | Norwegian University of Life Sciences | Meddoc Research Indonesia | Meddoc Research Taiwan","highestDevelopmentStatusID":"8","companyTruncated":"Meabco \/ Meddoc | Norwegian University of Life Sciences | Meddoc Research Indonesia | Meddoc Research Taiwan"},{"orgOrder":0,"company":"Meabco","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"DENMARK","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"BP-C2","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"Meabco","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Meabco \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Meabco \/ Undisclosed"},{"orgOrder":0,"company":"Meabco","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"DENMARK","productType":"Miscellaneous","year":"2020","type":"Funding","leadProduct":"BP-C2","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"Meabco","amount2":0.01,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","amount2New":0.01,"dosageForm":"Undisclosed","sponsorNew":"Meabco \/ National Institutes of Health","highestDevelopmentStatusID":"4","companyTruncated":"Meabco \/ National Institutes of Health"},{"orgOrder":0,"company":"Meabco","sponsor":"Meabco","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"BP-C2","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Meabco","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Meabco \/ Meabco","highestDevelopmentStatusID":"6","companyTruncated":"Meabco \/ Meabco"}]

    Find Clinical Drug Pipeline Developments & Deals by Meabco

    Menu

    Meabco

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Meabco

                            Denmark arrow
                            Neuroscience
                            Not Confirmed

                            Meabco

                            Denmark arrow
                            Neuroscience
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : BP-C2

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Study Phase : Preclinical

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Meabco's Drug Candidate Efficiently Mitigates Radiation-Induced Gastrointestinal Syndrome in Mice

                            Details : BP-C2 reduces mortality when administered 24 hours post-exposure in a murine model of severe, radiation-induced gastrointestinal acute radiation syndrome (GI-ARS).

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            October 19, 2020

                            Lead Product(s) : BP-C2

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Highest Development Status : Preclinical

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Meabco

                            Denmark arrow
                            Neuroscience
                            Not Confirmed

                            Meabco

                            Denmark arrow
                            Neuroscience
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : BP-C2

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Study Phase : Preclinical

                            Sponsor : National Institutes of Health

                            Deal Size : $5.9 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            Meabco Gets $5.9 M US Government Contract to Advance Its Bp-C2 Compound for Cutaneous Radiation Injuries

                            Details : This three-year contract consists of a one-year base period with two one-year optional periods that will allow Meabco to complete IND-enabling studies and advance BP-C2 as a therapy for treating the effects of unintentional radiation exposure.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            May 25, 2020

                            Lead Product(s) : BP-C2

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Highest Development Status : Preclinical

                            Sponsor : National Institutes of Health

                            Deal Size : $5.9 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Meabco

                            Denmark arrow
                            Neuroscience
                            Not Confirmed

                            Meabco

                            Denmark arrow
                            Neuroscience
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : BP-C1

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Meddoc | Norwegian University of Life Sciences | Meddoc Research Indonesia | Meddoc Research Taiwan

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Dose-finding Study of BP-C1 in Patients With Stage IV Breast Cancer

                            Details : BP-C1 is a Cytotoxic Drug drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Breast Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Cytotoxic Drug

                            Upfront Cash : Inapplicable

                            March 06, 2020

                            Lead Product(s) : BP-C1

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Meddoc | Norwegian University of Life Sciences | Meddoc Research Indonesia | Meddoc Research Taiwan

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Meabco

                            Denmark arrow
                            Neuroscience
                            Not Confirmed

                            Meabco

                            Denmark arrow
                            Neuroscience
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : BP-C2

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Recipient : Meddoc

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Recommended Dose Estimation of BP-C2

                            Details : BP-C2 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Prostatic Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            December 05, 2019

                            Lead Product(s) : BP-C2

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Recipient : Meddoc

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Meabco

                            Denmark arrow
                            Neuroscience
                            Not Confirmed

                            Meabco

                            Denmark arrow
                            Neuroscience
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : BP-C1

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Meddoc | Norwegian University of Life Sciences

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            BP-C1 Monotherapy in Patients With Metastatic Breast Cancer Cancer: Estimation of Optimal Duration of Treatmen...

                            Details : BP-C1 is a Cytotoxic Drug drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Breast Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Cytotoxic Drug

                            Upfront Cash : Inapplicable

                            December 28, 2018

                            Lead Product(s) : BP-C1

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Meddoc | Norwegian University of Life Sciences

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Meabco

                            Denmark arrow
                            Neuroscience
                            Not Confirmed

                            Meabco

                            Denmark arrow
                            Neuroscience
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : BP-C1

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Meddoc | Norwegian University of Life Sciences

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            BP-C1 in Short-term Treatment of Metastatic Pancreatic Cancer

                            Details : BP-C1 is a Cytotoxic Drug drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Pancreatic Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Cytotoxic Drug

                            Upfront Cash : Inapplicable

                            August 13, 2018

                            Lead Product(s) : BP-C1

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Meddoc | Norwegian University of Life Sciences

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Meabco

                            Denmark arrow
                            Neuroscience
                            Not Confirmed

                            Meabco

                            Denmark arrow
                            Neuroscience
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : BP-C1

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Meddoc | Norwegian University of Life Sciences

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            BP-C1 in Short-term Treatment of Thai Patients With Metastatic Breast Cancer

                            Details : BP-C1 is a Cytotoxic Drug drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Breast Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Cytotoxic Drug

                            Upfront Cash : Inapplicable

                            July 27, 2018

                            Lead Product(s) : BP-C1

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Meddoc | Norwegian University of Life Sciences

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Meabco

                            Denmark arrow
                            Neuroscience
                            Not Confirmed

                            Meabco

                            Denmark arrow
                            Neuroscience
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : BP-C1

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Meddoc | Norwegian University of Life Sciences

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            BP-C1 in Short-term Treatment of Patients With Metastatic Breast Cancer

                            Details : BP-C1 is a Cytotoxic Drug drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Breast Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Cytotoxic Drug

                            Upfront Cash : Inapplicable

                            May 26, 2016

                            Lead Product(s) : BP-C1

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Meddoc | Norwegian University of Life Sciences

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Meabco

                            Denmark arrow
                            Neuroscience
                            Not Confirmed

                            Meabco

                            Denmark arrow
                            Neuroscience
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : BP-C1

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            BP-C1 in Metastatic Breast Cancer Patients

                            Details : BP-C1 is a Cytotoxic Drug drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Breast Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Cytotoxic Drug

                            Upfront Cash : Inapplicable

                            May 23, 2013

                            Lead Product(s) : BP-C1

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth